Somatostatin_octretide for prevention of rebleeding from gastrointestinal angiodysplasias - SOPRANO
- Conditions
- study to investigate the efficacy of Octeoid LAR plus standard therapy versus standard therapy alone in patients with bleeding gastrointestinal angiodysplasias
- Registration Number
- EUCTR2005-005313-38-DE
- Lead Sponsor
- Klinikum rechts der Isar, Technical University of Munich
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 102
Inclusion Criteria
- patients about 18
- performed ÖGD, colosscopy or video pill
- one or more gastrotestinale haemorrage during the last three month
- detection of angiodysplasia
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
Exclusion Criteria
-Patients with bad general conditions
-other reasons for gastrointestinal bleeding (e. g. tumors, erosion, ulzera, varices)
-Hypertriglyceridaemie
-choledocholithiasis
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method